Guidance document: Global pharmacoeconomic model adaption strategies

Value in Health Regional Issues

Volumn 5, Issue , 2014, Pages 7-13

  Daniel Mullins, C ^a   Onwudiwe, Nneka C ^a   Branco de Araújo, Gabriela Tannus ^b   Chen, Wen ^c   Xuan, Jianwei ^d   Tichopád, Aleš ^e   Hu, Shanlian ^c  

^a UNIVERSITY OF MARYLAND SCHOOL OF PHARMACY   (United States)

^b AxiaBio Consulting   (Brazil)

^c FUDAN UNIVERSITY   (China)

^d PFIZER INC   (United States)

^e CEEOR Central and Eastern European Outcomes Research   (Czech Republic)

Author keywords

Cost effectiveness analysis; Health technology assessment; Pharmacoeconomic model

Indexed keywords

ARTICLE; CASE MIX; CONSENSUS DEVELOPMENT; COST EFFECTIVENESS ANALYSIS; DRUG FORMULARY; EVIDENCE BASED PRACTICE; HEALTH CARE PRACTICE; HEALTH CARE QUALITY; INTERVIEW; MEDICAL DECISION MAKING; MEDICAL EXPERT; PHARMACOECONOMICS; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROGRAM ACCEPTABILITY; SOCIAL ADAPTATION; STATISTICAL ANALYSIS; SYSTEMATIC REVIEW (TOPIC); TREATMENT OUTCOME; COST BENEFIT ANALYSIS; COST UTILITY ANALYSIS; DECISION MAKING; DOCUMENTATION; HEALTH CARE PLANNING; HEALTH CARE POLICY; HEALTH CARE UTILIZATION; HUMAN; JURISPRUDENCE; NONBIOLOGICAL MODEL; PHARMACOECONOMIC MODEL ADAPTION; QUALITY CONTROL; RESOURCE ALLOCATION; SOCIAL ACCEPTANCE;

EID: 84900806874     PISSN: 22121099     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vhri.2014.02.006     Document Type: Article

References (41)

1. Harris A., Buxton M., O'Brien B., Drummond F.R. Using economic evidence in reimbursement decisions for health technologies: experience of 4 countries. Expert Rev Pharmacoecon Outcomes Res 2001, 1:7-12.
2. Welte R., Feenstra T., Jager H., Leidl R. A decision chart for assessing and improving the transferability of economic evaluation results between countries. Pharmacoeconomics 2004, 22:857-876.
3. Pichon-Riviere A., Augustovski F., Garcia Marti S., et al. Transferability of health technology assessment reports in Latin America: an exploratory survey of researchers and decision makers. Int J Technol Assess Health Care 2012, 28:180-186.
4. Barbieri M., Drummond M., Willke R., et al. Variability of cost-effectiveness estimates for pharmaceuticals in Western Europe: lessons for inferring generalizability. Value Health 2005, 8:10-23.
5. Fuchs V.R. Economic Aspects of Health. A Conference Report/National Bureau of Economic Research 1982, University of Chicago Press, Chicago.
6. Krahn M., Gafni A. Discounting in the economic evaluation of health care interventions. Med Care 1993, 31:403-418.
7. Goeree R., He J., O'Reilly D., et al. Transferability of health technology assessments and economic evaluations: a systematic review of approaches for assessment and application. Clinicoecon Outcomes Res 2011, 3:89-104.
8. Koopmanschap M.A., Touw K.C., Rutten F.F. Analysis of costs and cost-effectiveness in multinational trials. Health Policy 2001, 58:175-186.
9. Ramsey S.D., Sullivan S.D. The burden of illness and economic evaluation for COPD. Eur Respir Rev 2003, 41(Suppl.). 29s-35.
10. Hjelmgren J., Berggren F., Andersson F. Health economic guidelines--similarities, differences and some implications. Value Health 2001, 4:225-250.
11. Rizzo J.D., Powe N.R. Methodological hurdles in conducting pharmacoeconomic analyses. Pharmacoeconomics 1999, 15:339-355.
12. O'Brien B.J. A tale of two (or more) cities: geographic transferability of pharmacoeconomic data. Am J Managed Care 1997, 3(Suppl.):S33-S39.
13. Chen N. The Behaviour of Relative Prices in the European Union: A Sectoral Analysis. CEPR Discussion Paper No. 3320 2002, University of Warwick, Department of Economics, Warwick.
14. Wild D., Grove A., Martin M., et al. Principles of good practice for the translation and cultural adaptation process for patient-reported outcomes (PRO) measures: report of the ISPOR Task Force for Translation and Cultural Adaptation. Value Health 2005, 8:94-104.
15. Chang W.C., Midodzi W.K., Westerhout C.M., et al. Are international differences in the outcomes of acute coronary syndromes apparent or real? A multilevel analysis. J Epidemiol Community Health 2005, 59:427-433.
16. Nordhaus W. Alternative measures of output in global economic-environmental models: purchasing power parity or market exchange rates?. Energy Econ 2007, 29:349-372.
17. Wennberg J., Gittelsohn Small area variations in health care delivery. Science 1973, 182(4117):1102-1108.
18. James B.C., Hammond M.E. The challenge of variation in medical practice. Arch Pathol Lab Med 2000, 124:1001-1003.
19. Fetter R.B., Shin Y., Freeman J.L., et al. Case mix definition by diagnosis-related groups. Med Care 1980, 18(2 Suppl.):1-53. (iii).
20. Frick A.P., Martin S.G., Shwartz M. Case-mix and cost differences between teaching and nonteaching hospitals. Med Care 1985, 23:283-295.
21. Laupacis A., Feeny D., Detsky A.S., Tugwell P.X. How attractive does a new technology have to be to warrant adoption and utilization? Tentative guidelines for using clinical and economic evaluations. CMAJ 1992, 146:473-481.
22. Garrison L.P., Neumann P.J., Erickson P., et al. Using real-world data for coverage and payment decisions: the ISPOR Real-World Data Task Force Report. Value Health 2007, 10:326-335.
23. Hollenbeck B.K., Miller D.C., Taub D.A., et al. The effects of adjusting for case mix on mortality and length of stay following radical cystectomy. J Urol 2006, 176:1363-1368.
24. Tarlov A.R., Ware J.E., Greenfield S., et al. The Medical Outcomes Study: an application of methods for monitoring the results of medical care. JAMA 1989, 262:925-930.
25. DerSimonian R., Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986, 7(3):177-188.
26. Brennan A., Akehurst R. Modelling in health economic evaluation. What is its place? What is its value? Pharmacoeconomics 2000, 17:445-459.
27. Bekkering G.E., Kleijnen J. Procedures and methods of benefit assessments for medicines in Germany. HEPAC 2008, 9(Suppl. 1):5-29.
28. Augustovski F., Iglesias C., Manca A., et al. Barriers to generalizability of health economic evaluations in Latin America and the Caribbean region. Pharmacoeconomics 2009, 27:919-929.
29. Goeree R., Burke N., O'Reilly D., et al. Transferability of economic evaluations: approaches and factors to consider when using results from one geographic area for another. Curr Med Res Opin 2007, 23:671-682.
30. Manca A., Willan A.R. 'Lost in translation': accounting for between-country differences in the analysis of multinational cost-effectiveness data. Pharmacoeconomics 2006, 24:1101-1119.
31. Drummond M., Barbieri M., Cook J., et al. Transferability of economic evaluations across jurisdictions: ISPOR Good Research Practices Task Force Report. Value Health 2009, 12:409-418.
32. Smith T.W., Tierce J.C. Designing and developing budget impact models suited for global adaptation. ISPOR CONNECTIONS. 2006. Available from:. [Accessed July 14, 2013]. http://www.ispor.org/news/articles/aug06/designing.asp.
33. Weinstein M.C., O'Brien B., Hornberger J., et al. Principles of good practice for decision analytic modeling in health-care evaluation: report of the ISPOR Task Force on Good Research Practices--Modeling Studies. Value Health 2003, 6:9-17.
34. Rawlins M.D., Culyer A.J. National Institute for Clinical Excellence and its value judgments. BMJ 2004, 329:224-227.
35. Wonderling D., Sawyer L., Fenu E., et al. National Clinical Guideline Centre cost-effectiveness assessment for the National Institute for Health and Clinical Excellence. Ann Intern Med 2011, 154:758-765.
36. Baltussen R., Ament A., Leidl R. Making cost assessments based on RCTs more useful to decision-makers. Health Policy 1996, 37:163-183.
37. Greiner W., Schöffski O., Graf v.d., Schulenburg J.-M. The transferability of international economic health-economic results to national study questions. HEPAC Health Econ Prev Care 2000, 1(2):94-102.
38. Pang F. Design, analysis and presentation of multinational economic studies: the need for guidance. Pharmacoeconomics 2002, 20:75-90.
39. Wordsworth S., Ludbrook A. Comparing costing results in across country economic evaluations: the use of technology specific purchasing power parities. Health Econ 2005, 14:93-99.
40. Fernandez L.A., Martin J.M., del Castillo J.D., et al. Sources of influence on medical practice. J Epidemiol Community Health 2000, 54:623-630.
41. Hutubessy R., Chisholm D., Edejer T.T. Generalized cost-effectiveness analysis for national-level priority-setting in the health sector. Cost Effec Resour Alloc 2003, 1:8.